Table 5.
Patterns of immunosuppression claims in patients with discordant indications of calcineurin inhibitor and antimetabolite use in claims compared with OPTN and the MRa
| Parameter | Discharge (n [%])
|
6 Mo (n [%])
|
1 Yr (n [%])
|
All Study Time Points (n [%])
|
|||||
|---|---|---|---|---|---|---|---|---|---|
| OPTNb | MRb | OPTNb | MRb | OPTNb | MRb | OPTNb | MRb | Total | |
| Total discordant | 37 (100) | 7 (100) | 20 (100) | 25 (100) | 14 (100) | 12 (100) | 71 (100) | 44 (100) | 115 (100) |
| Concordant claim present within an extended window of ±90 d | 7 (18.9) | 4 (57.1) | 8 (40.0) | 12 (48.0) | 5 (35.7) | 6 (50) | 20 (28.2) | 22 (50.0) | 42 (36.5) |
| Claim for another drug of same class at corresponding observation timec | 21 (56.8) | 1 (14.3) | 6 (30.0) | 6 (24.0) | 2 (14.3) | 1 (8.3) | 29 (40.8) | 8 (18.2) | 37 (32.2) |
| No claim for any drug within class at corresponding observation timec | 9 (24.3) | 2 (28.6) | 6 (30.0) | 7 (28.0) | 7 (50.0) | 5 (41.7) | 22 (31.0) | 14 (31.8) | 36 (31.3) |
a
Calcineurin inhibitor class comprises cyclosporine and tacrolimus. Antimetabolite class comprises azathioprine and MMF.
b
Data source compared with claims.
c
The window for claims ascertainment taken as ±30 d of the corresponding follow-up date, as per definition in primary analyses.